knowledge -WSS

knowledge

author：entertainment 2025-10-01 22:59:46 - browse：4

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： With psoriasis trial ahead, Alumis raises $259 million

knowledge

WSS

Anthony Fauci pushes back on GOP claims during Covid hearing

BD to buy Edwards patient monitoring unit for $4.2 billion

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

FDA approves Moderna’s RSV vaccine, its second licensed product

Fight over Supreme Court dialysis ruling puts kidney patients at risk

CDC marks new Covid

entertainment

knowledge

focus

Heart attack and stroke risk calculators need revising

Finland to offer bird flu vaccine to select groups of people, a possible global first

Medical leaders decry Supreme Court decision on affirmative action

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Walensky prepares to leave CDC — and Congress — behind

NEJM study link tiny plastics in blood vessels to heart problems

Medical records are filled with copy

Air quality improving but still lags in Black, Hispanic communities

United colonoscopy coverage change 'may cost lives,' doctors say

Senators tussle over abortion against the backdrop of a presidential campaign

explore

The problem with charging patients to message their doctors

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Headspace, Meta partner to launch VR meditation app for Quest

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Amylyx ALS drug failure raises questions and concerns

Eli Lilly’s Zepbound improved liver scarring in mid

knowledge

knowledge

Wikipedia

hotspot